The firm's technology can perform in-droplet centrifugation, 10-second cell lysis, and sound wave-based PCR on the surface of an inexpensive polymer chip.
SeqOnce, which was founded in 2014, has developed a technology for NGS library preparation that it says is significantly quicker than competing methods.
Twist continues to invest in NGS while growing its core synthetic biology business, and has filed a countercomplaint in its ongoing litigation with Agilent.
Circulomics, Bionano, Sage Science, RevoluGen, and others have been developing methods for extracting DNA hundreds of kilobases and up to megabases in length.
The company plans to use the funding to further develop its Xdrop technology, which allows users to partition millions of single molecules in droplets.
CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.
The round was led by Meritech Capital, with participation from Fidelity and Wells Fargo, and brings the company's total financing to date to $243 million.
Paragon and MGI Tech — a unit of BGI — have signed a distribution deal for certain of their respective next-generation sequencing panels and sample prep products.
Twist, which went public in October, reported that its revenues doubled this year due to increased sales of its synthetic DNA products and the introduction of NGS products.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
